drugset / Trial / NCT00650910

Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer

NCT00650910

Phase 1 Completed 17 enrolled GlaxoSmithKline
NaSingle-groupOpen-labelTreatment

Summary

This is a two part study looking at the effect of lapatinib on concentrations of digoxin in the blood when both drugs are dosed together in Part 1; and looking at the safety and antitumor effect of lapatinib when used together with possible additional anticancer therapy as chosen at the doctor's discretion.

Timeline

Start
2008-04-23
Primary completion
2009-07-10
Completion
2009-07-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.5 mg Oral
Subject Lapatinib Small molecule 1500 mg Oral

Indications